[go: up one dir, main page]

EP2007649A1 - Capsule en métal en deux parties, destinée à contenir des préparations pharmaceutiques pour inhalateurs à poudre - Google Patents

Capsule en métal en deux parties, destinée à contenir des préparations pharmaceutiques pour inhalateurs à poudre

Info

Publication number
EP2007649A1
EP2007649A1 EP07728095A EP07728095A EP2007649A1 EP 2007649 A1 EP2007649 A1 EP 2007649A1 EP 07728095 A EP07728095 A EP 07728095A EP 07728095 A EP07728095 A EP 07728095A EP 2007649 A1 EP2007649 A1 EP 2007649A1
Authority
EP
European Patent Office
Prior art keywords
capsule
amino
phenyl
fluoro
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07728095A
Other languages
German (de)
English (en)
Inventor
Dieter Hochrainer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP2007649A1 publication Critical patent/EP2007649A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the invention relates to novel two-piece capsules made of metal for receiving pharmaceutical active ingredients, drug mixtures and formulations for use in powder inhalers and a method for producing the capsule.
  • Capsules with pharmaceutical preparations are widely used in the therapy and diagnosis of diseases.
  • the capsules can be administered orally or come in certain medical devices, such as. B. in powder inhalers used.
  • the purpose of the capsule is to protect the active ingredient as well as the entire formulation from chemical or physical changes.
  • the physical changes include in particular changes that can change the application of the predetermined fine particle dose.
  • fine particle dose is understood to mean the dose that can reach the lungs of the patient.
  • the latter is influenced by the interactions of the micronized drug particles with each other as well as the interactions with the excipients. It has been found that, especially by changing the degree of moisture inside the package, these interactions can increase in such a way that the fine particle dose is significantly reduced. Such changes include the ingress of water into the package as well as the removal of water from inside the package.
  • the capsules consist of two parts, a capsule body (body) and a capsule cap (cap), which are telescoped into one another. But also multi-part capsules are known.
  • the capsules are usually made of gelatin, especially hard gelatin.
  • the capsules exist sometimes also from humans, easily digestible, water-soluble plastics, for example, to release the active ingredient in certain compartments of the gastrointestinal tract when administered orally.
  • EP 0143524 discloses a two-part capsule of material which is easily digested by humans, preferably gelatin.
  • EP 0460921 describes capsules of chitosan and starch, cereal powder, oligosaccharides, methacrylic acid-methyl acrylate, methacrylic acid-ethyl acrylate, hydroxypropylmethyl-cellulose acetate, succinate or phthalate.
  • the capsule material is characterized in that the content is released only in the large intestine.
  • GB 938828 discloses capsules for radioactive substances in therapeutic or diagnostic use.
  • the capsules are made of water-soluble gelatin, methylcellulose, polyvinyl alcohol or water-soluble non-toxic thermoplastics.
  • EP 1100474 discloses non-water soluble hydrophobic plastic capsules for use in a powder inhaler.
  • the materials used are often not very resistant to humidity, which is why the pharmaceutical grade of the ingredients can not be guaranteed for all climates. Especially in climate zone 4 (30 ° C / 70% relative humidity) conventional capsules can not be used.
  • EP 1414639 discloses a method for Sealing capsules for powder inhalers.
  • the capsule is coated with a hydrophobic material, such as a grease, wax or PEG.
  • the capsule can also be banded at the point of overlap between capsule top and bottom part with the above-mentioned materials.
  • Another framework condition is the size and wall thickness of the capsules to be welded, in particular the thin wall of such a capsule. This is necessary because the capsule is used in a commercial inhaler. There it has to be cut open or cut open in a simple way.
  • capsules are used for inhalation in appropriate inhalers.
  • An inhaler preferred for the present purposes is described, for example, in WO 94/28958, to which reference is hereby fully made.
  • suitable containers of the type according to the invention are inhalers as are ® known under the brand names HandiHaler ®, Spinhaler ®, Rotahaler ®, Aerolizer ®, FlowCaps ®, Turbo Spin ®, AIR DPI ®, Orbital ®, Directhaler and / or in DE 33 45 722 , EP 0 591 136, DE 43 18 455, WO 91/02558, FR-A-2 146 202, US-A-4 069 819, EP 666085, EP 869079, US Pat. No. 3,991,161, US Pat. No. 3,991,161, US Pat. No. 3,991,761, WO99 / 45987, WO
  • An ensemble consists of an inhaler for the inhalation of powdered medicaments and a two-part capsule, wherein the inhaler is characterized by a) an upwardly open, cup-shaped lower part, which has two opposite windows in the casing and a first at the edge of the opening B) has a plate which covers the opening of the lower part and has a second hinge element, c) an inhalation chamber for receiving the capsule, which is perpendicular to the Pldttenebene is formed on the lower part facing side of the plate and on which a button movable against a spring is provided, the button is provided with two ground needles, d) em upper part with a mouth tube and a d ⁇ tten hinge element, and e) a lid comprising the fourth hinge member, wherein the hinge members are one of the lower part, two of the plate, three of the upper part and four of the lid connected to each other
  • this is an inhaler of the brand HandiHaler ®
  • This inhaler is zeichne ⁇ sch shown in EP 1342483, Figure 6, page 5, which is incorporated in its entirety by reference
  • the materials used for the capsules their properties depending on the surrounding humidity change and / or are not always dimensionally stable
  • such a capsule for example in the climatic zone 4 due to the high Humidity can not be used because the Kapselmate ⁇ al absorbs the moisture so strong that the Formstabihtat is severely impaired and / or moisture penetrates into the interior of the capsule This has a negative impact on the pharmaceutical quality of the contents of the capsule.
  • Said materials also have several disadvantages in other different stages of life of the capsule from manufacture to use, and affect the usefulness of the capsule as a carrier of pharmaceutical preparations, the mode of administration of the ingredients, the shelf life of the ingredients and / or the usefulness of the capsule in certain countries.
  • the present invention has for its object to provide capsules for powder inhalers, which do not have the above-mentioned problems of conventional capsules and a method for producing the capsule.
  • the present invention relates to a metal capsule for receiving pharmaceutical active ingredients, active substance mixtures and formulations for
  • the capsules are in particular impermeable to water vapor and oxygen.
  • the capsule according to the invention consists of two parts, a capsule tub and a capsule lid, which can be connected together to form a stable, closed cavity of defined volume containing the drug, mixture or pharmaceutical formulation.
  • these capsules contain a single dose of the formulation.
  • the capsules are also called single-dose capsules in the context of the present invention.
  • the metal of the capsule is not digestible to humans, so that when taken orally, the active ingredient is not released. This has the advantage that accidental swallowing of the capsule does not cause lasting damage to the capsule
  • the metal must be deformable so that the undulating projections and depressions can be pressed without tearing.
  • the metal must also be solderable or weldable depending on the type of closure.
  • the metal must be thin-walled and have the necessary shape stability.
  • the metals should not interact with the drugs used or excipients.
  • the following metals are used: stainless steel, which is suitable for example for laser welding or copper-containing metals, such as brass or bronze, which can be soldered well.
  • the metal capsule is so stable that it withstands a force of up to 15 N along the longitudinal axis or the transverse axis.
  • the advantage is that the capsule is better adapted to the stresses involved in manufacturing, filling, packaging, transporting and the like. to act on the capsule.
  • the production of the capsule tub and the cover is basically done by cold forming according to known methods of metal processing.
  • the interface between capsule tub and capsule lid is welded, pressed, crimped or soldered.
  • the method of cold pressure welding is also considered.
  • the lid is placed after filling the tub with the desired amount of powder and pressed the carrier film and the lid with a suitably shaped heat sinks against each other.
  • the heat sink derives the heat occurring during the soldering or welding process.
  • heat-conducting materials such as copper and alloys. The only exception is in cold press welding, where no heat sink is necessary.
  • FIG. The preferred embodiment of the capsule is shown in FIG.
  • the tub connected to the lid forms a flat box.
  • the thickness of the walls of the tub and lid can vary over the entire range.
  • the wall thickness is generally greater in the rounded areas of the tub and lid or at the location of the body where the bead is formed than in the areas where the walls are rectilinear.
  • the walls of the tub and lid have a thickness of 0.02 mm to 0.2 mm, preferably the capsule has an average wall thickness of 0.05 mm.
  • the diameter of the capsule is in a range of 3 to 15 mm, preferably between 5 and 8 mm.
  • the height of the capsule is 1 to 5 mm, preferably 2 to 3 mm.
  • the capsule according to the invention is suitable for receiving powdered pharmaceutical formulation suitable for inhalation.
  • the compounds mentioned below can be used alone or in combination for use in the device according to the invention.
  • W is a pharmacologically active agent and (for example) selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HI antihistamines, P AF - antagonists and PI3-kinase inhibitors.
  • two- or three-fold combinations of W can be combined and used for application in the device according to the invention. Exemplary combinations of W would be: W represents a betamimetics combined with an anticholinergic,
  • Corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists, W represents an anticholinergic agent combined with a betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists, W represents a corticosteroid combined with a PDE4 Inhibitors, EGFR inhibitors or LTD4 antagonists
  • W represents a PDE4 inhibitor combined with an EGFR inhibitor or LTD4
  • W represents an EGFR inhibitor combined with a LTD4 antagonist.
  • Preferred betamimetics for this purpose are compounds selected from the group consisting of albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharines, isoprenaline, levosalbutamol, mabuterol, meluadrine, metaproterenol , Orciprenaline, Pirbuterol, Procaterol, Reproterol, Rimiterol, Ritodrine, Salmefamol, Salmeterol, Soterenol, Sulphone terol, Terbutaline, Tiaramide, Tolubuterol, Zinterol, CHF-1035, HOKU-81, KUL-1248 and
  • the acid addition salts of the betamimetics are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydroxides citrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred anticholinergic compounds are compounds which are selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospium salts the chloride salt, tolterodine.
  • the cations are the pharmacologically active ones
  • the aforementioned salts may preferably contain chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulfonate, wherein chloride, bromide , Iodide, sulfate, methanesulfonate or p-toluenesulfonate are preferred as counterions.
  • the chlorides, bromides, iodides and methanesulfonates are particularly preferred.
  • anticholinergics are selected from the salts of the formula AC-I
  • X is a single negatively charged anion, preferably an anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-toluenesulfonate, preferably a singly negatively charged anion, more preferably an anion selected from the group consisting of fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, most preferably bromide, is optionally in the form of theirs Racemates, enantiomers or hydrates. Of particular importance are those drug combinations which contain the enantiomers of the formula AC-I-ene
  • R is either methyl or ethyl and where X ⁇ may have the abovementioned meanings.
  • the compound of formula AC-2 may also be present in the form of the base AC-2 base.
  • Preferred corticosteroids are compounds selected from the group consisting of beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone, RPR - 106541, NS-126, ST-26 and
  • any reference to steroids includes reference to their optional salts or derivatives, hydrates or solvates.
  • Examples of possible salts and derivatives of steroids may be: alkali metal salts, such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • Preferred PDE4 inhibitors here are compounds selected from the group consisting of enprofylline, theophylline, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirimilast, arofylline, atizoram, D-4418, bay 198004, BY343, CP-325,366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V- 11294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and N- (3,5-dichloro-1-oxo-pyridin-4-yl) -4-difluoromethoxy-3-cyclopropylmethoxybenzamide
  • the acid addition salts of the PDE4 inhibitors selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate are preferred ,
  • Preferred LTD4 antagonists here are compounds selected from the group consisting of montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078 , VUF-K-8707, L-733321 and - 1 - (((R) - (3- (2- (6,7-Difluoro-2-quinolinyl) ethenyl) phenyl) -3- (2- (2-hydroxy-2-propyl) phenyl) thio) methylcyclopropane -acetic acid,
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • salts or derivatives which the LTD4-antagonists are capable of forming include: alkali metal salts, such as, for example, sodium or potassium salts, alkaline earth salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogenphosphates, palmitates, pivalates or furoates.
  • alkali metal salts such as, for example, sodium or potassium salts, alkaline earth salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogenphosphates, palmitates, pivalates or furoates.
  • Preferred EGFR inhibitors are compounds selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred dopamine agonists are compounds selected from the group consisting of bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexole, roxindole, ropinirole, talipexole,
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, Hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • HI-antihistamines here are preferably compounds used, which are selected from the group consisting of epinastine, cetirizine, azelastine,
  • these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydrooxalate, hydrosuccinate, hydrobenzoate, and hydro-p-toluenesulfonate.
  • substance formulations or substance mixtures all inhalable compounds are used, such as e.g. also inherently macromolecules, as disclosed in EP 1 003 478.
  • substances, substance formulations or substance mixtures are used for the treatment of respiratory diseases, which are used in the inhalation area.
  • the capsules according to the invention together with an inhalable drug are used in a powder inhaler, as already described at the beginning.
  • This Powder inhaler is in ready for sale surrounded by a commercial packaging.
  • the capsule well and the capsule lid can be interconnected by various methods.
  • Figure 1 exemplifies one way of soldering a metal capsule, but is for illustration only, without limiting the scope of the invention.
  • a rotational symmetry is assumed, but this is not a prerequisite.
  • a pan is pressed.
  • the solder joint At the edge of the tub is the solder joint.
  • wave-shaped elevations and depressions are pressed on the edge of the tub.
  • the solder On the outermost elevation, the solder is applied.
  • the tub is juxtaposed with a lid pressed from a cover foil, which likewise has wave-shaped elevations and depressions which correspond with the corresponding elevations and depressions of the tub.
  • the lid After filling the tub with the desired amount of powder, the lid is placed and pressed the carrier film and the lid with suitably shaped heat sinks against each other.
  • the heat sink derives the heat occurring during the soldering or welding process, so that no harmful effect of heat on the powder.
  • heat conducting materials such as copper and its alloys. The only exception is in cold press welding, where no heat sink is necessary.
  • the heat sinks penetrate in particular into the recesses of the carrier film and the lid, so that there the heat is removed from the soldering process and does not reach the powder can.
  • annular soldering iron are pressed from both sides in the region of the solder on the carrier film and the lid, so that the solder connects the films gas-tight.
  • the soldering iron are removed and after a short cooling time, the heatsink.
  • the contact surfaces of the soldering iron are designed so that a quick heat transfer to the solder surfaces is achieved.
  • the protruding elevations and depressions of tub and lid touch each other, so that the powder can not come into contact with the solder.
  • e.g. elongated containers are housed side by side.
  • the area can be well utilized when triangular, square, rectangular or hexagonal containers are placed on a surface. In these cases it may be advantageous to round the corners. Other shapes may also be used for the containers.
  • the opening of the container is preferably done by piercing or cutting. This may be done by passing air or other gas through the container in an aerodynamically favorable flow to empty the container.
  • the flow of air can be effected by the inhalation of the patient, but it can also be a gas from a pressure vessel or a small pump (piston, bellows, blisters, etc.) can be used.
  • the dispersion of the powder can be triggered by the patient's breath.
  • the bumps and depressions on the edge of the container may be carried out differently than shown in Figure 1. This not only affects the number of surveys and wells, but also their height. For example, the outermost elevation of the trough may be higher than the inner trough, so that only the elevation is affected when joining the elevation with solder.
  • all materials for these containers come into consideration, which can be soldered together at not too high temperatures and allow the necessary deformation.
  • these are for soldering highly copper-containing materials and a Lot consisting mainly of tin.
  • the solder joints are already connected before filling the tub with powder with solder, so that no solder must be applied during soldering. Also, any necessary flux may have been previously eliminated.
  • Stainless steel sheets whose edges are joined by laser welding are suitable for the production of welded capsules.
  • the production of the capsule according to the invention takes place in several steps. In principle, it is expedient to punch the tub and the lid from the foils before closing, because otherwise the closure of the capsule can be easily damaged during punching.
  • the foil for the tub is unrolled from a spool, the foil cleaned as needed, the tub pressed, the tub punched out, the tub held in tool carrier, the flux and the solder applied to the outer elevation, the Unwrapped foil for the lid, unrolled the foil if necessary, pressed the lid, punched out the lid, held the lid with tool carrier, placed the tub on the heat sink, covered the raised areas and depressions on the edge of the tub, and then troughed it Filling the jack, remove the cover from the edge of the tub, place the lid on the pan, insert the heat sink for the lid and push the lid onto the pan, hot
  • soldering iron is brought to the soldering point and pressed, the soldering iron removed, the soldering point allowed to cool, the upper heat sink removed and the capsule ejected.
  • the tightness of the capsule according to the invention can be checked by inserting the capsule and measuring the moisture content at the beginning and end of the test.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

L'invention concerne de nouvelles capsules en métal en deux parties, destinées à contenir des préparations pharmaceutiques utilisables dans des inhalateurs à poudre, ainsi qu'un procédé de fabrication de ces capsules. Les capsules sont particulièrement étanches à la vapeur d'eau et à l'oxygène.
EP07728095A 2006-04-15 2007-04-13 Capsule en métal en deux parties, destinée à contenir des préparations pharmaceutiques pour inhalateurs à poudre Ceased EP2007649A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006017698A DE102006017698A1 (de) 2006-04-15 2006-04-15 Zweiteilige Kapsel aus Metall zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
PCT/EP2007/053630 WO2007118857A1 (fr) 2006-04-15 2007-04-13 Capsule en métal en deux parties, destinée à contenir des préparations pharmaceutiques pour inhalateurs à poudre

Publications (1)

Publication Number Publication Date
EP2007649A1 true EP2007649A1 (fr) 2008-12-31

Family

ID=38190605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07728095A Ceased EP2007649A1 (fr) 2006-04-15 2007-04-13 Capsule en métal en deux parties, destinée à contenir des préparations pharmaceutiques pour inhalateurs à poudre

Country Status (6)

Country Link
US (2) US20090148515A1 (fr)
EP (1) EP2007649A1 (fr)
JP (1) JP2009533191A (fr)
CA (1) CA2649028A1 (fr)
DE (1) DE102006017698A1 (fr)
WO (1) WO2007118857A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3756490A (en) * 1971-09-15 1973-09-04 Univ Johns Hopkins Apparatus for sealing packages
US4891165A (en) * 1988-07-28 1990-01-02 Best Industries, Inc. Device and method for encapsulating radioactive materials
GB9909357D0 (en) * 1999-04-24 1999-06-16 Glaxo Group Ltd Medicament carrier
US7171965B2 (en) * 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
AU2001250901A1 (en) * 2000-03-27 2001-10-08 Dura Pharmaceuticals, Inc. Containers for individual doses of an inhalable pharmaceutical
GB0106046D0 (en) * 2001-03-12 2001-05-02 Glaxo Group Ltd Canister
GB0418738D0 (en) * 2004-08-23 2004-09-22 3M Innovative Properties Co Medicinal aerosol formulation receptacle and production thereof
DE102005035705A1 (de) * 2005-07-27 2007-02-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arzneimittelblister

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007118857A1 *

Also Published As

Publication number Publication date
DE102006017698A1 (de) 2007-10-18
CA2649028A1 (fr) 2007-10-25
US20120285451A1 (en) 2012-11-15
US20090148515A1 (en) 2009-06-11
JP2009533191A (ja) 2009-09-17
WO2007118857A1 (fr) 2007-10-25

Similar Documents

Publication Publication Date Title
EP2004262B1 (fr) Réservoir d'inhalateur, et inhalateur multi-doses
EP2408571B1 (fr) Reservoir et pulverisateur
EP2066380B1 (fr) Inhalateur
EP1948274B1 (fr) Aiguille pour percer des capsules de poudre pour l'inhalation
EP2254630A1 (fr) Inhalateurs de poudre
WO2007118343A1 (fr) Dispositif d'émission de médicaments, magasins à médicaments à cet effet, et procédé pour prélever un médicament d'une chambre à médicament
WO2007118858A1 (fr) Inhalateur
WO2007116002A1 (fr) Inhalateur
EP2175826A1 (fr) Fermeture étanche de gélules remplies d'un médicament
EP2178589A1 (fr) Inhalateur à poudre
WO2007048763A1 (fr) Inhalateur avec embout ayant une fonction de protection microbiologique
WO2007110403A1 (fr) Aérosols de dosage pour l'administration de préparations pharmaceutiques
EP2170730A1 (fr) Nouvel agent pharmaceutique poudreux contenant du tiotropium et du salmétérol ainsi que du lactose en tant qu'agent auxiliaire
EP2091571B1 (fr) Procédé de stérilisation d'un récipient en feuille
EP2020220A1 (fr) Scellement hermétique de capsules remplies de médicaments
WO2007118341A1 (fr) Dispositif d'émission de médicaments
EP2007649A1 (fr) Capsule en métal en deux parties, destinée à contenir des préparations pharmaceutiques pour inhalateurs à poudre
EP2244686A1 (fr) Procédé et dispositif pour remplir des gélules
EP2001536A1 (fr) Emballage pour inhalateur de poudre multidose avec proprietes optimisees de purge
WO2007048764A2 (fr) Absorption du gaz propulseur d'aerosols-doseurs pourvus d'emballages
WO2009056603A1 (fr) Capsule destinée à contenir des formulations de principes actifs pharmaceutiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081030

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

17Q First examination report despatched

Effective date: 20090616

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20100820